Related Experiment Videos
Split virus influenza vaccination in children: an evaluation of efficacy
Insights
This study evaluated the influenza vaccine MFV-Ject in children aged 4-13. The vaccine showed a good overall serological response with minimal side-effects, indicating favorable efficacy and tolerability in pediatric populations.
Area of Science:
- Pediatric Immunology
- Vaccinology
- Virology
Background:
- Influenza poses a significant health risk to children.
- Assessing the immunogenicity and safety of influenza vaccines in pediatric populations is crucial.
Purpose of the Study:
- To evaluate the serological response and reactogenicity of a split virus influenza vaccine in children.
- To determine the efficacy of the MFV-Ject vaccine in a pediatric cohort.
Main Methods:
- Twenty-seven children (4-13 years) received two 0.5 ml doses of MFV-Ject vaccine, one month apart.
- Vaccine composition included A/Philippines/2/82 (H3N2), A/Brazil/11/78 (H1N1), and B/Singapore/222/79 strains.
- Serological response and side-effects were monitored post-vaccination.
Main Results:
- A good overall serological response was observed across all vaccine strains.
- The B group virus elicited a slightly lower response, potentially due to low prior exposure.
- Children over 10 years demonstrated a higher serological response.
- Minimal side-effects were reported, indicating good vaccine tolerability.
Conclusions:
- The MFV-Ject influenza vaccine demonstrated a favorable reactogenicity/efficacy ratio in children.
- The vaccine is a potentially effective option for pediatric influenza prevention.
- Further studies may explore responses in different age groups and with varying prior exposure levels.
Abstract:
Twenty-seven children aged between 4 and 13 years were given two injections of a split virus influenza vaccine (MFV-Ject, Institut Merieux) at a dose of 0.5 ml and an interval of 1 month. Each vaccination contained A/Philippines/2/82 (H3 N2) 10 micrograms HA, A/Brazil/11/78 (H1 N1) 10 micrograms HA, B/Singapore/222/79 15 micrograms HA. The overall serological response was good although the B group virus produced slightly less response; however, no children were seropositive to B prior to vaccination, reflecting a low previous exposure. Children aged over 10 years showed a generally higher serological response. Side-effects were minimal. A favourable reactogenicity/efficacy ratio was found.